Details
Stereochemistry | RACEMIC |
Molecular Formula | C16H19N3S |
Molecular Weight | 285.407 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(CN1C2=C(SC3=C1N=CC=C3)C=CC=C2)N(C)C
InChI
InChIKey=OQJBSDFFQWMKBQ-UHFFFAOYSA-N
InChI=1S/C16H19N3S/c1-12(18(2)3)11-19-13-7-4-5-8-14(13)20-15-9-6-10-17-16(15)19/h4-10,12H,11H2,1-3H3
Molecular Formula | C16H19N3S |
Molecular Weight | 285.407 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
DescriptionSources: https://www.drugbank.ca/drugs/DB08802Curator's Comment: description was created based on several sources, including
https://www.drugs.com/international/isothipendyl.html | https://www.ncbi.nlm.nih.gov/pubmed/22677929 | https://www.ncbi.nlm.nih.gov/pubmed/13792589 | https://www.ncbi.nlm.nih.gov/pubmed/14157559
Sources: https://www.drugbank.ca/drugs/DB08802
Curator's Comment: description was created based on several sources, including
https://www.drugs.com/international/isothipendyl.html | https://www.ncbi.nlm.nih.gov/pubmed/22677929 | https://www.ncbi.nlm.nih.gov/pubmed/13792589 | https://www.ncbi.nlm.nih.gov/pubmed/14157559
Isothipendyl is a first generation H1 antagonist (antihistamine) and anticholinergic used as an antipruritic. It is nowadays scarcely used in the first line relief of allergies due to the anticholinergic side effect of somnolence but does have some limited use through topical application in the relief of insect bites and related itching (pruritus).
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL231 Sources: https://www.ncbi.nlm.nih.gov/pubmed/4150325 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Calmogel Approved UseUnknown |
Doses
Dose | Population | Adverse events |
---|---|---|
1 % single, topical Recommended Dose: 1 % Route: topical Route: single Dose: 1 % Sources: Page: p.429 |
unhealthy, 41 n = 41 Health Status: unhealthy Condition: Dermatisis Age Group: 41 Sex: F Population Size: 41 Sources: Page: p.429 |
Disc. AE: Allergic contact dermatitis... AEs leading to discontinuation/dose reduction: Allergic contact dermatitis Sources: Page: p.429 |
72 mg multiple, oral (max) Studied dose Dose: 72 mg Route: oral Route: multiple Dose: 72 mg Sources: Page: p.160 |
unhealthy n = 72 Health Status: unhealthy Condition: Urticaria | sensitization dermatitis|dermatoses Sex: M+F Population Size: 72 Sources: Page: p.160 |
Disc. AE: Weakness generalised... AEs leading to discontinuation/dose reduction: Weakness generalised (1 patient) Sources: Page: p.160 |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Allergic contact dermatitis | Disc. AE | 1 % single, topical Recommended Dose: 1 % Route: topical Route: single Dose: 1 % Sources: Page: p.429 |
unhealthy, 41 n = 41 Health Status: unhealthy Condition: Dermatisis Age Group: 41 Sex: F Population Size: 41 Sources: Page: p.429 |
Weakness generalised | 1 patient Disc. AE |
72 mg multiple, oral (max) Studied dose Dose: 72 mg Route: oral Route: multiple Dose: 72 mg Sources: Page: p.160 |
unhealthy n = 72 Health Status: unhealthy Condition: Urticaria | sensitization dermatitis|dermatoses Sex: M+F Population Size: 72 Sources: Page: p.160 |
PubMed
Title | Date | PubMed |
---|---|---|
Phototoxic and photoprotective effects of topical isothipendyl. | 1995 Apr |
|
Spectrophotometric determination of molybdenum(VI) using isothipendyl hydrochloride and pipazethate hydrochloride in alloy steels and soil samples. | 2001 Sep |
|
Spectrophotometric studies on the investigation of chromium in environmental samples. | 2003 Jan |
|
Bis[N,N-dimethyl-1-(10H-pyrido[3,2-b][1,4]benzothia-zin-10-yl)propan-2-aminium] tetrakis-(thio-cyanato-κN)cobaltate(II). | 2010 Jun 16 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/13792589
The dosage of isothipendyl in children was 6 to 8 mg. daily given as a syrup containing 2 mg. per teaspoonful. In adults the dosage varied from one 4 mg. tablet thrice daily to two 12 mg. sustained-action tablets thrice daily
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 18:44:56 GMT 2023
by
admin
on
Fri Dec 15 18:44:56 GMT 2023
|
Record UNII |
WVZ7K9P0JY
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
D04AA22
Created by
admin on Fri Dec 15 18:44:57 GMT 2023 , Edited by admin on Fri Dec 15 18:44:57 GMT 2023
|
||
|
WHO-VATC |
QD04AA22
Created by
admin on Fri Dec 15 18:44:57 GMT 2023 , Edited by admin on Fri Dec 15 18:44:57 GMT 2023
|
||
|
WHO-ATC |
R06AD09
Created by
admin on Fri Dec 15 18:44:57 GMT 2023 , Edited by admin on Fri Dec 15 18:44:57 GMT 2023
|
||
|
WHO-VATC |
QR06AD09
Created by
admin on Fri Dec 15 18:44:57 GMT 2023 , Edited by admin on Fri Dec 15 18:44:57 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
3781
Created by
admin on Fri Dec 15 18:44:57 GMT 2023 , Edited by admin on Fri Dec 15 18:44:57 GMT 2023
|
PRIMARY | |||
|
207-578-5
Created by
admin on Fri Dec 15 18:44:57 GMT 2023 , Edited by admin on Fri Dec 15 18:44:57 GMT 2023
|
PRIMARY | |||
|
CHEMBL2111066
Created by
admin on Fri Dec 15 18:44:57 GMT 2023 , Edited by admin on Fri Dec 15 18:44:57 GMT 2023
|
PRIMARY | |||
|
100000082856
Created by
admin on Fri Dec 15 18:44:57 GMT 2023 , Edited by admin on Fri Dec 15 18:44:57 GMT 2023
|
PRIMARY | |||
|
C170083
Created by
admin on Fri Dec 15 18:44:57 GMT 2023 , Edited by admin on Fri Dec 15 18:44:57 GMT 2023
|
PRIMARY | |||
|
28012
Created by
admin on Fri Dec 15 18:44:57 GMT 2023 , Edited by admin on Fri Dec 15 18:44:57 GMT 2023
|
PRIMARY | RxNorm | ||
|
C008214
Created by
admin on Fri Dec 15 18:44:57 GMT 2023 , Edited by admin on Fri Dec 15 18:44:57 GMT 2023
|
PRIMARY | |||
|
Isothipendyl
Created by
admin on Fri Dec 15 18:44:57 GMT 2023 , Edited by admin on Fri Dec 15 18:44:57 GMT 2023
|
PRIMARY | |||
|
DTXSID5048267
Created by
admin on Fri Dec 15 18:44:57 GMT 2023 , Edited by admin on Fri Dec 15 18:44:57 GMT 2023
|
PRIMARY | |||
|
WVZ7K9P0JY
Created by
admin on Fri Dec 15 18:44:57 GMT 2023 , Edited by admin on Fri Dec 15 18:44:57 GMT 2023
|
PRIMARY | |||
|
689
Created by
admin on Fri Dec 15 18:44:57 GMT 2023 , Edited by admin on Fri Dec 15 18:44:57 GMT 2023
|
PRIMARY | |||
|
m6543
Created by
admin on Fri Dec 15 18:44:57 GMT 2023 , Edited by admin on Fri Dec 15 18:44:57 GMT 2023
|
PRIMARY | Merck Index | ||
|
482-15-5
Created by
admin on Fri Dec 15 18:44:57 GMT 2023 , Edited by admin on Fri Dec 15 18:44:57 GMT 2023
|
PRIMARY | |||
|
DB08802
Created by
admin on Fri Dec 15 18:44:57 GMT 2023 , Edited by admin on Fri Dec 15 18:44:57 GMT 2023
|
PRIMARY | |||
|
1507
Created by
admin on Fri Dec 15 18:44:57 GMT 2023 , Edited by admin on Fri Dec 15 18:44:57 GMT 2023
|
PRIMARY | |||
|
SUB08339MIG
Created by
admin on Fri Dec 15 18:44:57 GMT 2023 , Edited by admin on Fri Dec 15 18:44:57 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |